The group focuses on studying cardiometabolic diseases using advanced imaging techniques to understand how cardiometabolic risk factors affect different organs. In our laboratory, we use cutting-edge technologies such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and vascular ultrasound to conduct a comprehensive analysis of the impact of these factors.

Thanks to hybrid techniques like PET/CT and PET/MRI, we can non-invasively assess both the anatomy and function of organs, providing a complete view in a single imaging session. In collaboration with the Progression of Early Subclinical Atherosclerosis (PESA-CNIC-Santander) study, we were the first to discover, in a clinical setting, how cardiometabolic risk factors increase bone marrow activity, a phenomenon associated with a higher risk of early atherosclerosis. Furthermore, using PET/MRI, we have demonstrated how metabolic syndrome and insulin resistance alter myocardial metabolism by modifying its energy substrate and reducing its efficiency. Additionally, with advanced techniques such as perfusion MRI, we assess microvascular function in the heart and its relationship with cardiometabolic risk factors. Our group’s approach is not limited to studying the impact of risk factors on isolated organs; we also investigate how organs interact with each other and how these interactions, modulated by risk factors, contribute to the development and progression of cardiometabolic diseases.

The ultimate goal of our research is to develop personalized, early prevention strategies based on the early identification of changes caused by cardiometabolic risk factors in various systems.